157 related articles for article (PubMed ID: 24167380)
1. Serum anti-CCNY autoantibody is an independent prognosis indicator for postoperative patients with early-stage nonsmall-cell lung carcinoma.
Ma L; Yue W; Teng Y; Zhang L; Gu M; Wang Y
Dis Markers; 2013; 35(5):317-25. PubMed ID: 24167380
[TBL] [Abstract][Full Text] [Related]
2. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis.
Yue W; Zhao X; Zhang L; Xu S; Liu Z; Ma L; Jia W; Qian Z; Zhang C; Wang Y; Yang X
Clin Lung Cancer; 2011 Jan; 12(1):43-50. PubMed ID: 21273179
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance and diagnostic value of Survivin autoantibody in non-small cell lung cancer patients].
Ma L; Yue W; Zhang L; Wang Y; Zhang C; Yang X
Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):706-12. PubMed ID: 20673487
[TBL] [Abstract][Full Text] [Related]
5. An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer.
Wu WB; Yie SM; Ye SR; Xie K; Zhang JB; Cao M; Chen J; He X; Ma XL; Zhang J
Ann Thorac Surg; 2018 Jun; 105(6):1664-1670. PubMed ID: 29453962
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
7. Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of nonsmall cell lung cancer.
Liang W; Lv T; Shi X; Liu H; Zhu Q; Zeng J; Yang W; Yin J; Song Y
Medicine (Baltimore); 2016 Sep; 95(37):e4608. PubMed ID: 27631209
[TBL] [Abstract][Full Text] [Related]
8. Establishing a detection method for CCNY: a potentially significant clinical investigative marker in NSCLC patients.
Ma L; Gu M; Teng Y; Li W
Onco Targets Ther; 2019; 12():921-932. PubMed ID: 30774378
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum sMICA levels in non-small cell lung cancer.
Wang LP; Niu H; Xia YF; Han YL; Niu P; Wang HY; Zhou QL
Eur Rev Med Pharmacol Sci; 2015 Jun; 19(12):2226-30. PubMed ID: 26166647
[TBL] [Abstract][Full Text] [Related]
10. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
11. High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer.
Lu J; Wang Y; Yan M; Feng P; Yuan L; Cai Y; Xia X; Liu M; Luo J; Li L
Oncotarget; 2016 Jul; 7(27):41758-41766. PubMed ID: 27248178
[TBL] [Abstract][Full Text] [Related]
12. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of cyclin Y in non-small cell lung cancer is associated with cancer cell proliferation.
Yue W; Zhao X; Zhang L; Liu Z; Ma L; Jia W; Qian Z; Zhang C; Wang Y; Yang X; Xu S
Sci China Life Sci; 2010 Apr; 53(4):511-6. PubMed ID: 20596919
[TBL] [Abstract][Full Text] [Related]
14. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
15. Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer.
Wang Z; Cai M; Weng Y; Zhang F; Meng D; Song J; Zhou H; Xie Z
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1353-61. PubMed ID: 25544672
[TBL] [Abstract][Full Text] [Related]
16. Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer.
Dai N; Cao XJ; Li MX; Qing Y; Liao L; Lu XF; Zhang SH; Li Z; Yang YX; Wang D
PLoS One; 2013; 8(3):e58001. PubMed ID: 23472128
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.
Su K; Zhang T; Wang Y; Hao G
World J Surg Oncol; 2016 Aug; 14(1):224. PubMed ID: 27733164
[TBL] [Abstract][Full Text] [Related]
18. ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
Fan W; Yang H; Xue H; Sun Y; Zhang J
Int J Clin Exp Pathol; 2015; 8(5):5503-8. PubMed ID: 26191257
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of HMGB-1 and TGF-β Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer.
Jakubowska K; Naumnik W; Niklińska W; Chyczewska E
Adv Exp Med Biol; 2015; 852():49-58. PubMed ID: 25753556
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
